These results suggested that JFP-Ps could alleviate inflammation and enhance immune barrier function of the small intestine in obese rats via inhibiting the expression of pro-inflammatory genes and activating SCFA- and GPR41/GPR43-related signaling pathways in the small intestine of obesity rats. This evidence concerns the gene FFAR2 and obesity disorder.